Persistent CD-19 depletion by rituximab is cost-effective in maintaining remission in calcineurin-inhibitor dependent podocytopathy

Raja Ramachandran, Joyita Bharati, Indu Rao, Ahmed W. Kashif, Ritambhra Nada, Ranjana Minz, Krishan L. Gupta, Harbir S. Kohli

Research output: Contribution to journalArticle

5 Citations (Scopus)

Fingerprint Dive into the research topics of 'Persistent CD-19 depletion by rituximab is cost-effective in maintaining remission in calcineurin-inhibitor dependent podocytopathy'. Together they form a unique fingerprint.

Medicine & Life Sciences